{
  "consolidation_metadata": {
    "timestamp": "2025-09-17T12:58:34.585760",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "picos",
    "total_consolidated_picos": 38,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_picos": [
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, with Child-Pugh class A liver function and ECOG performance status 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "AT",
        "DE",
        "EN",
        "FR",
        "DK",
        "PT",
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
        "adults with advanced or unresectable HCC in adults who have not had previous systemic treatment, only if: • they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
        "adult patients with advanced or non-resettable HCC",
        "treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
        "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy"
      ],
      "Original_Comparator_Variants": [
        "sorafenib",
        "Sorafenib"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, with Child-Pugh class A liver function and ECOG performance status 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "EN",
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "adults with advanced or unresectable HCC in adults who have not had previous systemic treatment, only if: • they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "adult patients with advanced or non-resettable HCC"
      ],
      "Original_Comparator_Variants": [
        "lenvatinib",
        "Lenvima (lenvatinib)"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, with Child-Pugh class A liver function and ECOG performance status 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab plus bevacizumab",
      "Countries": [
        "ES",
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "advanced or unresectable hepatocellular carcinoma that has not previously been treated with any other systemic therapy",
        "adult patients with advanced or non-resettable HCC"
      ],
      "Original_Comparator_Variants": [
        "atezolizumab plus bevacizumab",
        "Tecentriq (atezolizumab) plus bevacizumab"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, with Child-Pugh class A liver function and ECOG performance status 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "DE",
        "EN",
        "AT",
        "ES"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma",
        "most patients with advanced hepatocellular carcinoma",
        "patients with advanced or unresectable hepatocellular carcinoma or a tumour localization that cannot be locally controlled or resected and with an ECOG status of 0 1 points",
        "patients with advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A"
      ],
      "Original_Comparator_Variants": [
        "best supportive care",
        "BSC best supportive care"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, with Child-Pugh class A liver function and ECOG performance status 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo",
      "Countries": [
        "ES",
        "NL"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable hepatocellular carcinoma",
        "patients with advanced hepatocellular carcinoma"
      ],
      "Original_Comparator_Variants": [
        "placebo"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, with Child-Pugh class A liver function and ECOG performance status 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "ES",
        "SE"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable hepatocellular carcinoma",
        "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab"
      ],
      "Original_Comparator_Variants": [
        "lenvatinib"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, with Child-Pugh class A liver function and ECOG performance status 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "ES",
        "SE"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable hepatocellular carcinoma",
        "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab"
      ],
      "Original_Comparator_Variants": [
        "sorafenib"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, with Child-Pugh class A liver function and ECOG performance status 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab and bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A)"
      ],
      "Original_Comparator_Variants": [
        "atezolizumab and bevacizumab"
      ]
    },
    {
      "Population": "Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, with Child-Pugh class A liver function and ECOG performance status 0 or 1, when combination therapy is inappropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "tremelimumab-durvalumab combination",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate"
      ],
      "Original_Comparator_Variants": [
        "tremelimumab-durvalumab combination"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma in the second line after first line atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE",
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma in the second line after first line atezolizumab-bevacizumab",
        "second-line patients who have previously received bevacizumab with atezolizumab"
      ],
      "Original_Comparator_Variants": [
        "lenvatinib",
        "leninivat"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma in the second line after first line atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE",
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma in the second line after first line atezolizumab-bevacizumab",
        "second-line patients who have previously received bevacizumab with atezolizumab"
      ],
      "Original_Comparator_Variants": [
        "sorafenib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma in the second line after first line atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "SE",
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma in the second line after first line atezolizumab-bevacizumab",
        "second-line patients who have previously received bevacizumab with atezolizumab"
      ],
      "Original_Comparator_Variants": [
        "cabozantinib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma in the second line after first line atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma in the second line after first line atezolizumab-bevacizumab"
      ],
      "Original_Comparator_Variants": [
        "regorafenib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma in the second line after first line atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma in the second line after first line atezolizumab-bevacizumab"
      ],
      "Original_Comparator_Variants": [
        "ramucirumab"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma following progression on first-line tyrosine kinase inhibitor",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "SE",
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with tyrosine kinase inhibitor",
        "patients who are well tolerant of sorafenib"
      ],
      "Original_Comparator_Variants": [
        "regorafenib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma following progression on first-line tyrosine kinase inhibitor",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with tyrosine kinase inhibitor"
      ],
      "Original_Comparator_Variants": [
        "cabozantinib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma following progression on first-line tyrosine kinase inhibitor",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with tyrosine kinase inhibitor"
      ],
      "Original_Comparator_Variants": [
        "ramucirumab"
      ]
    },
    {
      "Population": "Patients previously treated with sorafenib with alpha-fetoprotein (AFP) ≥ 400 ng/ml",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml"
      ],
      "Original_Comparator_Variants": [
        "ramucyrumab"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE",
      "Countries": [
        "AT",
        "DE",
        "IT",
        "AT"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced HCC",
        "patients with HCC with evidence of a survival benefit from TACE versus supportive therapy (BSC)",
        "cirrhotic (max Child-Pugh B) patients with unresectable M0 multi-nodular HCC, in the absence of portal thrombosis"
      ],
      "Original_Comparator_Variants": [
        "TACE"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE plus sorafenib",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with advanced HCC"
      ],
      "Original_Comparator_Variants": [
        "TACE + Sorafenib"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with advanced or unresectable hepatocellular carcinoma",
        "patients with HCC with evidence of a survival benefit from TACE versus supportive therapy (BSC)"
      ],
      "Original_Comparator_Variants": [
        "best supportive care"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "conventional TACE",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with HCC in whom conventional TACE and drug-eluting TACE can be considered as equivalent procedures"
      ],
      "Original_Comparator_Variants": [
        "conventional TACE"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "drug-eluting TACE",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with HCC in whom conventional TACE and drug-eluting TACE can be considered as equivalent procedures"
      ],
      "Original_Comparator_Variants": [
        "drug-eluting TACE"
      ]
    },
    {
      "Population": "Patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab with bevacizumab",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with (not locally treatable) HCC"
      ],
      "Original_Comparator_Variants": [
        "atezolizumab with bevacizumab"
      ]
    },
    {
      "Population": "Patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "arterial chemoembolization",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable HCC"
      ],
      "Original_Comparator_Variants": [
        "arterial chemoembolization"
      ]
    },
    {
      "Population": "Patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radioactive iodine-131 treatment",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable HCC"
      ],
      "Original_Comparator_Variants": [
        "radioactive Iodine 131 treatment"
      ]
    },
    {
      "Population": "Patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "systemic chemotherapy (doxorubicin or cisplatin)",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable HCC"
      ],
      "Original_Comparator_Variants": [
        "systemic chemotherapy (doxorubicin or cisplatin)"
      ]
    },
    {
      "Population": "Patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "hormonal therapy with tamoxifen",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable HCC"
      ],
      "Original_Comparator_Variants": [
        "hormonal therapy with tamoxifen"
      ]
    },
    {
      "Population": "Patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "subcutaneous octreotide therapy",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Original_Population_Variants": [
        "patients with unresectable HCC"
      ],
      "Original_Comparator_Variants": [
        "subcutaneous octreotide therapy"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "local hepatic therapies",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "local hepatic therapies"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "transarterial chemoembolization",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "transarterial chemoembolization"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "transarterial embolization",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "transarterial embolization"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radiotherapy",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "radiotherapy"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "supportive care",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "supportive care"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "systemic chemotherapy",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "systemic chemotherapy"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radiofrequency ablation",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "radiofrequency ablation"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "microwave ablation",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "microwave ablation"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "other ablations (laser ablation, cryoablation, HIFU, irreversible electroporation)",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "other ablations (laser ablation, cryoablation, HIFU, irreversible electroporation)"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "alcohol injection",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "alcohol injection"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "acetic acid injection",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "acetic acid injection"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "liver resection",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "liver resection"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "liver transplantation",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "liver transplantation"
      ]
    },
    {
      "Population": "Patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation"
      ],
      "Original_Comparator_Variants": [
        "placebo"
      ]
    },
    {
      "Population": "Patients with hepatocellular carcinoma in whom initiation of curative treatment or continuation of locoregional or local palliative treatment is not possible or considered medically inappropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best care regimen available",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Original_Population_Variants": [
        "patients with hepatocellular carcinoma in whom initiation of curative treatment or (continuation) of locoregional or local palliative treatment is not possible or considered medically inappropriate (hepatocell carcinomas)"
      ],
      "Original_Comparator_Variants": [
        "best care regimen available"
      ]
    }
  ]
}